Ozen, Seza http://orcid.org/0000-0003-2883-7868
Ben-Cherit, Eldad
Foeldvari, Ivan
Amarilyo, Gil http://orcid.org/0000-0002-3888-429X
Ozdogan, Huri
Vanderschueren, Steven
Marzan, Katherine
Kahlenberg, J Michelle http://orcid.org/0000-0002-4006-8945
Dekker, Elise
De Benedetti, Fabrizio
Koné-Paut, Isabelle http://orcid.org/0000-0001-8939-5763
Clinical trials referenced in this document:
Documents that mention this clinical trial
OP0063 Canakinumab treatment in patients with colchicine-resistant FMF (CRFMF), HIDS/MKD and traps: efficacy in the 16 weeks randomised controlled phase and maintenance of disease control and safety at week 40
https://doi.org/10.1136/annrheumdis-2017-eular.2194
OP0272 LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH COLCHICINE-RESISTANT FAMILIAL MEDITERRANEAN FEVER: RESULTS FROM THE RANDOMISED PHASE 3 CLUSTER TRIAL
https://doi.org/10.1136/annrheumdis-2020-eular.522
Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial
https://doi.org/10.1136/annrheumdis-2020-217419
Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study
https://doi.org/10.1136/annrheumdis-2015-209031
THU0570 Long-term efficacy and safety of canakinumab in patients with colchicine-resistant fmf (CRFMF), traps and hids/mkd: results from the pivotal phase 3 cluster trial
https://doi.org/10.1136/annrheumdis-2018-eular.5246
OP0254 CANAKINUMAB IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RECURRENT FEVER SYNDROMES: RESULTS FROM A PHASE 3 TRIAL (CLUSTER)
https://doi.org/10.1136/annrheumdis-2019-eular.1176
THU0509 Improvement of disease activity in patients with colchicine-resistant FMF, HIDS/MKD and traps assessed by autoinflammatory disease activity index (AIDAI): results from the cluster trial
https://doi.org/10.1136/annrheumdis-2017-eular.5655
Documents that mention this clinical trial
OP0063 Canakinumab treatment in patients with colchicine-resistant FMF (CRFMF), HIDS/MKD and traps: efficacy in the 16 weeks randomised controlled phase and maintenance of disease control and safety at week 40
https://doi.org/10.1136/annrheumdis-2017-eular.2194
OP0272 LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH COLCHICINE-RESISTANT FAMILIAL MEDITERRANEAN FEVER: RESULTS FROM THE RANDOMISED PHASE 3 CLUSTER TRIAL
https://doi.org/10.1136/annrheumdis-2020-eular.522
Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial
https://doi.org/10.1136/annrheumdis-2020-217419
Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study
https://doi.org/10.1136/annrheumdis-2015-209031
THU0570 Long-term efficacy and safety of canakinumab in patients with colchicine-resistant fmf (CRFMF), traps and hids/mkd: results from the pivotal phase 3 cluster trial
https://doi.org/10.1136/annrheumdis-2018-eular.5246
OP0254 CANAKINUMAB IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RECURRENT FEVER SYNDROMES: RESULTS FROM A PHASE 3 TRIAL (CLUSTER)
https://doi.org/10.1136/annrheumdis-2019-eular.1176
THU0509 Improvement of disease activity in patients with colchicine-resistant FMF, HIDS/MKD and traps assessed by autoinflammatory disease activity index (AIDAI): results from the cluster trial
https://doi.org/10.1136/annrheumdis-2017-eular.5655
Funding for this research was provided by:
Novartis Pharma